<DOC>
	<DOCNO>NCT01453803</DOCNO>
	<brief_summary>The intent clinical study answer question : 1 . Is propose treatment safe 2 . Is treatment effective improve disease pathology patient Parkinson 's Disease clinical outcome .</brief_summary>
	<brief_title>Study Assess Safety Effects Autologous Adipose-Derived SVF Cells Patients With Parkinson 's Disease</brief_title>
	<detailed_description>This open-label , non-randomized multi-center patient sponsor study Adipose-Derived Stromal Cells ( ASC ) implantation use catheter delivery system . ASCs derive patient 's adipose-derived tissue . Liposuction use local anesthesia syringe collection perform collect adipose tissue specimen subsequent process isolate stem cell . The cell deliver via catheter Vertebral Artery intravenously .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Males Females Age 18 80 year . Patient current diagnosis PD motor complication ( confirmed neurologist ) per standard criterion guideline . Responsiveness Levodopa dopa agonist . This define improvement Off On UPDRS least 33 % Motor UPDRS . PD Stage 2.5 , 3 &amp; 4 HOEHN &amp; YAHR staging . Stable Parkinsonian medication 60 day prior surgical therapy . MRI show gross atrophy pathology brain . Patients score less 19 MontgomeryAsberg Rating Scale ( MADRS ) Depression . NO Significant cognitive impairment.MMSE &gt; 21 . Up date age gender appropriate cancer screen per American Cancer Society History intracranial surgery implantation device Parkinson 's disease two year prior treatment . History psychiatric disorder like schizophrenia psychotic disorder . History malignancy , exception treat cutaneous squamous cell basal cell carcinoma , within 5 year . Contraindication MRI Females pregnant nursing female childbearing potential unwilling maintain contraceptive therapy duration study Life expectancy &lt; 6 month due concomitant illness . Exposure investigational drug procedure within 1 month prior study entry enrol concurrent study may confound result study . Active infectious disease . Patients know tested positive HIV , HTLV , HBV , HCV , CMV ( IgM &gt; IgG ) and/or syphilis evaluate expert patient eligibility base patient 's infectious status Any illness , Investigator 's judgement , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result Patients chronic immunosuppressive transplant therapy Systolic blood pressure ( supine ) â‰¤90 mmHg ; Resting heart rate &gt; 100 bpm ; Active clinical infection treat antibiotic within one week enrollment . Known drug alcohol dependence factor interfere study conduct interpretation result opinion investigator suitable participate . History cancer ( nonmelanoma skin cancer insitu cervical cancer ) last two year . Unwilling and/or able give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Liposuction</keyword>
	<keyword>ADSC</keyword>
	<keyword>ASC</keyword>
	<keyword>stem cell</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Parkinson 's</keyword>
	<keyword>therapy</keyword>
</DOC>